Item 8.01 Other Events.

On January 5, 2023, Salarius Pharmaceuticals, Inc. (the "Company") issued a press release announcing that, on December 27, 2022, the U.S. Patent and Trademark Office issued U.S. Patent No. 11,535,603, titled "Deuterium-enriched Piperidinonyl-oxoisoindolinyl Acetamides and Methods of Treating Medical Disorders Using Same." The issued claims cover the composition of matter for novel molecular glue degraders including the Company's preclinical cereblon-binding compound, SP-3204, through September 2037. A copy of the press release is filed herewith as Exhibit 99.1, and the information contained therein is incorporated by reference to this Item 8.01.

Item 9.01 Financial Statements and Exhibits.



(d) Exhibits
Exhibit No.             Description

             99.1         Press Release of Salarius Pharmaceuticals, Inc., dated January 5, 2023
              104       Cover Page Interactive Data File (embedded within the inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses